Baxter Reports Solid First Quarter Financial Results and Raises Full-Ye...($558 $525 6% (2%) ---...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008
$558 $525 6% (2%)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Baxter excluding Transfusion
Therapies $2,833 $2,587 10% 4%
--------------------------------------------------------------------------
--------------------------------------------------------------------------
Transfusion Therapies (4) $44 $88 (50%) (51%)
--------------------------------------------------------------------------
--------------------------------------------------------------------------
TOTAL BAXTER $2,877 $2,675 8% 2%
==========================================================================
(1) Previously referred to as BioSurgery.
(2) Principally includes vaccines, sales of plasma to third parties, and
recombinant FIX (BeneFIX). Sales of BeneFIX ceased as of June 30,
2007.
(3) Prior year BioScience sales data has been reclassified as described in
Note 4.
(4) The TT business was sold on February 28, 2007. The results of
operations of the TT business were previously reported in the
BioScience business. The TT totals above include sales of TT products
through the date of divestiture, as well as revenues associated with
manufacturing, distribution and other services provided by the company
to the buyer of the TT business post-divestiture.
BAXTER INTERNATIONAL INC.
Key Product Line Sales by US and International
Periods Ending March 31, 2008 and 2007
(unaudited)
($ in millions)
-------------------------------------
'/>"/>
| SOURCE Baxter International Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
(Date:12/16/2009)... University (NTU) signed the Memorandum of Understanding in ... (CNRS) and the Thales Group of Companies to ... parties are meeting again in Singapore to inaugurate ... , Located at the Research Techno Plaza, ... in science and technology to develop innovations in ...
(Date:12/16/2009)... Blood America, Inc. (OTC Bulletin Board: CBAI), the ... http://www.cordblood-america.com ) focused on bringing the life ... policy, to families nationwide and internationally, said today ... total of $1.4 million so far in the ... for the year now tops $10 million. ,, ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/15/2009)... Calif., Dec. 15 Epeius Biotechnologies Corporation, ... genetic medicine, gained international validation of the cutting-edge ... , when scientists around the world rediscovered the ... major locus of cancer pathogenesis and disease progression, ... Recently, scientists at the NIH National Cancer Institute ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3[0] New Singapore-French nanotech lab opens at NTU[0] Cord Blood America Says 2009 Debt Reduction Tops $10 Million[0] AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma[0] Scientists Rediscover Gene Target for Cancer Therapy
... Pharmaceuticals,Inc. (Nasdaq: AMLN ) will be presenting at ... FL on Thursday, May 1,2008 at 9:20 a.m. ET ... Executive Officer of Amylin Pharmaceuticals, will be providing a,corporate ... be webcast, and a,recording will be made available following ...
... America (Nasdaq: DCAI ) announced today that it ... 7, 2008, after the close of the,market. The company ... first quarter 2008 earnings release the following morning, May ... participating in the May 8, 2008 conference call,may dial ...
... Congenital Heart Disease Database and, the Further Transition ... ... April 25 VentriPoint(TM) Diagnostics,Ltd. (TSX: VPT) today announced ... with the University of Washington to,collaborate on projects that ...
Other Biology Technology:Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date 2VentriPoint, University of Washington Sign Research and Technology Development Agreement 2(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
(Date:12/16/2009)... REDWOOD SHORES, Calif. and PALM HARBOR, Fla., ... ("CIC") (OTC Bulletin Board: CICI), a leading ... process automation in the financial industry* and ... and Docubase Systems Inc. ("Docubase"), a leading ... announced today that they have entered an ...
(Date:12/16/2009)... -- National Instruments (Nasdaq: NATI ), ... and DENSO Robotics, a leader and pioneer ... announced their collaboration to integrate NI measurement ... The collaboration increases productivity and performance in ... In today,s trend toward high-mix, low-volume manufacturing, ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5AHA Board Elects John Bluford Chair Elect Designate 52607 1AHA Board Elects John Bluford Chair Elect Designate 52607 2AHA Board Elects John Bluford Chair Elect Designate 52607 3Immucor Announces Fiscal Fourth Quarter Results 52606 1Immucor Announces Fiscal Fourth Quarter Results 52606 2Immucor Announces Fiscal Fourth Quarter Results 52606 3Immucor Announces Fiscal Fourth Quarter Results 52606 4Immucor Announces Fiscal Fourth Quarter Results 52606 5Immucor Announces Fiscal Fourth Quarter Results 52606 6Immucor Announces Fiscal Fourth Quarter Results 52606 7Immucor Announces Fiscal Fourth Quarter Results 52606 8Immucor Announces Fiscal Fourth Quarter Results 52606 9Immucor Announces Fiscal Fourth Quarter Results 52606 10Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 13172 1Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results 13172 2... dramatic reduction in the impact of malaria is in prospect ... Guinea early next year. Success in the trial would open ... with this debilitating and often fatal disease - over 500,000,000 ... Medical Research is collaborating with the Papua New Guinea Institute ...
... Francisco VA Medical Center (SFVAMC) and the University of ... with lymphocytic bronchitis, which is thought to lead to ... failure of transplanted lungs. , The researchers hope their ... more accurate standard test for chronic lung rejection, as ...
... number of living Florida panthers has grown from a previously ... of a controversial breeding effort to improve the genetic health ... assessment. , Hybrid kittens born to panthers brought into the ... of becoming adults as do purebred ones," reports a paper ...
Other Biology News:Old drug, new tricks: Prospects for slashing the impact of malaria 2Researchers identify genes associated with lung transplant rejection 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 2Research suggests fitness of Florida panthers improved by limited breeding with Texas animals 3Request Info...
... The Nick Translation System is ideal for ... The Nick Translation System: Provides five ... nucleotide incorporation Yields >10 8 ... control DNA to monitor the performance of ...
ABI 432 Resins • Gln(Trt) Peptide Synthesis Column...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |